Amplatzer Piccolo Gets Green Light: Abbott's New Device Offers Hope for Tiniest Hearts

Abbott just scored major regulatory wins for its Amplatzer Piccolo Delivery System, winning both FDA clearance and CE Mark approval. But what does this really mean for premature infants struggling with a dangerous heart condition?

The system targets patent ductus arteriosus (PDA), a condition where a crucial blood vessel fails to close after birth. When this happens, excess blood floods the lungs, making it brutally hard for newborns to breathe. It’s particularly devastating for the tiniest patients—infants weighing as little as two pounds.

Why Piccolo Changes the Game

Here’s where Abbott’s innovation matters: the traditional approach to treating PDA requires multiple catheters and complex maneuvering in fragile patients. The new Amplatzer Piccolo Delivery System strips away that complexity. It uses just one catheter, dramatically simplifying the intervention while maintaining precision.

The design itself is a breakthrough. Its shorter, softer construction allows physicians to place the device with surgical accuracy in vulnerable newborns, reducing procedural risks that already make this population so high-risk. This is crucial—when you’re operating on a two-pound infant, every millimeter counts.

Expert Validation

Dr. Evan Zahn, professor of cardiology and pediatrics at Cedars-Sinai Medical Center, doesn’t mince words: “This is a major step forward in treating PDA in premature infants. The system improves precision and confidence when treating very small and vulnerable patients.”

That confidence matters. Pediatric cardiologists dealing with extremely premature infants need every advantage, and the Piccolo’s streamlined approach gives them exactly that—fewer tools, cleaner procedures, better outcomes.

The dual regulatory approvals signal that both U.S. and European authorities see genuine clinical value here. For neonatal care units worldwide, Abbott’s Amplatzer Piccolo Delivery System represents meaningful progress in treating one of the most common heart defects in preterm babies.